NCT07090161Phase 2Recruiting

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

Study sponsor: Vanda Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-10Estimated
Enrollment · participants240Estimated
Source updated2026-02-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source